These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27618663)

  • 1. Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.
    Pascolutti R; Sun X; Kao J; Maute RL; Ring AM; Bowman GR; Kruse AC
    Structure; 2016 Oct; 24(10):1719-1728. PubMed ID: 27618663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of pH-dependent interactions between PD-1 and PD-L1 immune checkpoint proteins from molecular dynamics.
    Klyukin K; Alexandrov V
    Proteins; 2020 Sep; 88(9):1162-1168. PubMed ID: 32105362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1 and PD-L1.
    Liu W; Huang B; Kuang Y; Liu G
    Mol Biosyst; 2017 May; 13(5):892-900. PubMed ID: 28327740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD).
    Du J; Qin Y; Wu Y; Zhao W; Zhai W; Qi Y; Wang C; Gao Y
    Cell Commun Signal; 2018 Jun; 16(1):25. PubMed ID: 29879980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human PD-1 binds differently to its human ligands: a comprehensive modeling study.
    Viricel C; Ahmed M; Barakat K
    J Mol Graph Model; 2015 Apr; 57():131-42. PubMed ID: 25723350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
    Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
    Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.
    Mitteldorf C; Berisha A; Pfaltz MC; Broekaert SMC; Schön MP; Kerl K; Kempf W
    Am J Surg Pathol; 2017 Jul; 41(7):998-1004. PubMed ID: 28504999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
    Zak KM; Kitel R; Przetocka S; Golik P; Guzik K; Musielak B; Dömling A; Dubin G; Holak TA
    Structure; 2015 Dec; 23(12):2341-2348. PubMed ID: 26602187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery.
    Tang S; Kim PS
    Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24500-24506. PubMed ID: 31727844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.
    He G; Zhang H; Zhou J; Wang B; Chen Y; Kong Y; Xie X; Wang X; Fei R; Wei L; Chen H; Zeng H
    J Exp Clin Cancer Res; 2015 Nov; 34():141. PubMed ID: 26581194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153.
    Baban B; Liu JY; Qin X; Weintraub NL; Mozaffari MS
    PLoS One; 2015; 10(4):e0124059. PubMed ID: 25902191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
    Merelli B; Massi D; Cattaneo L; Mandalà M
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
    Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.
    Lim H; Chun J; Jin X; Kim J; Yoon J; No KT
    Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.
    Maute RL; Gordon SR; Mayer AT; McCracken MN; Natarajan A; Ring NG; Kimura R; Tsai JM; Manglik A; Kruse AC; Gambhir SS; Weissman IL; Ring AM
    Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6506-14. PubMed ID: 26604307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
    Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
    Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.
    Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR
    Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
    Black M; Barsoum IB; Truesdell P; Cotechini T; Macdonald-Goodfellow SK; Petroff M; Siemens DR; Koti M; Craig AW; Graham CH
    Oncotarget; 2016 Mar; 7(9):10557-67. PubMed ID: 26859684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.